Eli Lilly’s Alzheimer’s drug slows progression, carries risk of brain swelling,…
Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.Eli Lilly and Co. is seeking U.S. Food and Drug Administration (FDA) approval of donanemab.…